María Victoria Mateos Manteca-rekin lankidetzan egindako argitalpenak (2)

2016

  1. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2010

  1. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

    European Journal of Haematology, Vol. 84, Núm. 4, pp. 359-361